Perrigo Co. PLC isn’t making it easy for a bloc of board members to succeed in pushing to divest the firm’s Rx generic business. The company's finances are stabilizing despite challenges such as ongoing price erosion hammering the prescription generics sector.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?